Journal article

Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-olabel, Australian study

Alex Disney, Peter De Jersey, Geoff Kirkland, Murty Mantha, John A Charlesworth, Martin Gallagher, David Harris, Hilton Gock, George J Mangos, Jamie MacMillan, Wei Liu, Ajit Viswalingam

NEPHROLOGY | WILEY | Published : 2007


AIM: Darbepoetin alfa, an erythropoiesis-stimulating protein, has a longer serum half-life than recombinant human erythropoietin, allowing less-frequent administration. This study aimed to demonstrate that once-monthly (QM) darbepoetin alfa administration would maintain haemoglobin (Hb) concentrations in subjects with chronic kidney disease (CKD) not receiving dialysis who had previously been administered darbepoetin alfa every 2 weeks (Q2W). METHODS: This was a multicentre study in which subjects with CKD receiving stable Q2W darbepoetin alfa doses and with stable Hb (100-130 g/L) were started on QM darbepoetin alfa dosing. The initial QM darbepoetin alfa dose was equivalent to the cumulati..

View full abstract

University of Melbourne Researchers